Of mice and men: a curious tale of disappearing plaques and tumbling stocks

Objective: To describe the events surrounding the recent termination of Elan Pharmaceutical's phase 2a trial of beta amyloid immunisation for Alzheimer's disease. Conclusions: Excessive and uncritical enthusiasm for new treatments can lead to negative clinical and financial outcomes.